Aarti Pharma Labs Stock Screener | Share Price & Fundamental Analysis
AARTIPHARM
Pharmaceuticals
Screen Aarti Pharma Labs share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹730.65
▼
-11.45 (-1.54%)
Share Price BSE
₹729.55
▼
-12.95 (-1.74%)
Market Cap
₹6,745.97 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
3.33
EPS (TTM)
₹30.06
Dividend Yield
0.66%
Debt to Equity
0.19
52W High
₹964.90
52W Low
₹584.55
Operating Margin
18.00%
Profit Margin
6.70%
Revenue (TTM)
₹418.00
EBITDA
₹74.00
Net Income
₹28.00
Total Assets
₹2,906.00
Total Equity
₹1,990.00
Aarti Pharma Labs Share Price History - Stock Screener Chart
Screen AARTIPHARM historical share price movements with interactive charts. Analyze price trends and patterns.
Aarti Pharma Labs Company Profile - Fundamental Screener
Screen Aarti Pharma Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AARTIPHARM shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0LRU01027
Aarti Pharma Labs Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen AARTIPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 2,906 | 2,582 | 2,244 | 2,040 | 0 |
| Current Assets | 1,322 | 1,346 | 1,163 | 1,028 | 0 |
| Fixed Assets | 1,137 | 1,033 | 926 | 782 | 0 |
| Liabilities | |||||
| Total Liabilities | 2,906 | 2,582 | 2,244 | 2,040 | 0 |
| Current Liabilities | 259 | 131 | 85 | 73 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 1,990 | 1,757 | 1,559 | 1,387 | 0 |
| Share Capital | 45 | 45 | 45 | 0 | 0 |
| Reserves & Surplus | 1,945 | 1,712 | 1,513 | 1,341 | 0 |
Screen AARTIPHARM income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 418 | 388 | 562 | 543 | 463 | 558 | 508 | 450 | 441 | 459 | 486 | 472 | 532 | 457 | 463 |
| Expenses | 344 | 293 | 418 | 409 | 364 | 459 | 388 | 353 | 352 | 374 | 405 | 385 | 441 | 371 | 385 |
| EBITDA | 74 | 95 | 144 | 134 | 98 | 99 | 120 | 97 | 89 | 85 | 81 | 87 | 91 | 86 | 78 |
| Operating Profit % | 18.00% | 24.00% | 26.00% | 24.00% | 20.00% | 17.00% | 23.00% | 21.00% | 20.00% | 19.00% | 16.00% | 18.00% | 17.00% | 19.00% | 16.00% |
| Depreciation | 25 | 23 | 23 | 23 | 21 | 20 | 19 | 19 | 18 | 17 | 16 | 16 | 17 | 14 | 14 |
| Interest | 11 | 7 | 7 | 10 | 6 | 5 | 5 | 5 | 4 | 4 | 6 | 5 | 6 | 4 | 5 |
| Profit Before Tax | 39 | 65 | 115 | 101 | 72 | 74 | 96 | 74 | 67 | 64 | 59 | 65 | 69 | 68 | 60 |
| Tax | 11 | 16 | 26 | 27 | 17 | 18 | 31 | 21 | 15 | 17 | 16 | 17 | 18 | 16 | 11 |
| Net Profit | 28 | 50 | 88 | 74 | 55 | 56 | 65 | 53 | 52 | 47 | 43 | 48 | 51 | 52 | 49 |
| EPS | 3.08 | 5.46 | 9.75 | 8.16 | 6.03 | 6.12 | 7.20 | 5.82 | 5.72 | 5.20 | 4.73 | 5.26 | 5.64 | 5.72 | 5.39 |
Aarti Pharma Labs Cash Flow Screener - Liquidity Fundamentals
Screen AARTIPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|
| Operating Activities | 332 | 216 | 250 | -44 | 0 |
| Investing Activities | -414 | -215 | -158 | -139 | 0 |
| Financing Activities | 65 | 10 | -164 | 260 | 0 |
| Net Cash Flow | -17 | 12 | -71 | 78 | 0 |
Screen AARTIPHARM shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 42.88% | 43.72% | 44.29% | 44.66% | 46.10% | 46.46% | 46.46% | 46.46% |
| FII Holding | 8.02% | 7.35% | 7.36% | 8.64% | 7.38% | 7.06% | 8.32% | 8.16% |
| DII Holding | 6.96% | 7.80% | 7.53% | 10.36% | 11.35% | 11.47% | 9.97% | 9.91% |
| Govt Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public Holding | 35.39% | 34.43% | 34.10% | 30.39% | 29.45% | 29.57% | 29.71% | 29.74% |
| Other Holding | 6.74% | 6.69% | 6.71% | 5.94% | 5.71% | 5.43% | 5.52% | 5.72% |
| Shareholder Count | 190,655 | 187,039 | 196,314 | 185,111 | 185,436 | 189,012 | 204,122 | 215,796 |
Aarti Pharma Labs Dividend Screener - Share Yield Analysis
Screen AARTIPHARM dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹5.00 | 0.66% |
| 2024-March | ₹3.00 | 0.40% |
| 2023-March | ₹2.00 | 0.46% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Aarti Pharma Labs Index Membership - Market Screener Classification
Screen AARTIPHARM by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Aarti Pharma Labs Market Events Screener - Corporate Actions
Screen AARTIPHARM market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 9.96% | ||
| Dividend | ₹ 2.50 /share | 20.75% | ||
| 2025-11-09 | 2025-11-09 | Quarterly Result Announcement | NA | 3.94% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -5.93% |
| 2025-05-10 | 2025-05-10 | Quarterly Result Announcement | NA | 1.74% |
| 2025-02-14 | 2025-02-14 | Dividend | ₹ 2.50 /share | 17.73% |
| 2025-02-05 | 2025-02-05 | Quarterly Result Announcement | NA | 4.01% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -0.82% |
| 2024-08-07 | 2024-08-07 | Annual General Meeting | NA | -2.08% |
| 2024-07-31 | 2024-07-31 | Dividend | ₹ 1.00 /share | 22.39% |
| 2024-02-16 | 2024-02-19 | Dividend | ₹ 2.00 /share | -2.63% |
Aarti Pharma Labs Competitors Screener - Peer Comparison
Screen AARTIPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Aarti Pharma Labs Company Announcements - News Screener
Screen AARTIPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-06 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-27 | Closure of Trading Window | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-09 | Financial Results For Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-09 | Board Meeting Outcome for Board Meeting Outcome For Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-11-09 | Board Meeting Outcome for Board Meeting Outcome For Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-11-09 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-27 | Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-13 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-10-08 | Ex-Parte Ad-Interim Injunction Order Regarding Pharmaceutical Drug Product Containing Ruxolitinib And/Or Ruxolitinib Phosphate API | View |
| 2025-10-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-25 | Closure of Trading Window | View |
| 2025-09-24 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-09-23 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-09-23 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-09-23 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |